JP6893052B1 - 投与計画提案システム、方法およびプログラム - Google Patents

投与計画提案システム、方法およびプログラム Download PDF

Info

Publication number
JP6893052B1
JP6893052B1 JP2020112023A JP2020112023A JP6893052B1 JP 6893052 B1 JP6893052 B1 JP 6893052B1 JP 2020112023 A JP2020112023 A JP 2020112023A JP 2020112023 A JP2020112023 A JP 2020112023A JP 6893052 B1 JP6893052 B1 JP 6893052B1
Authority
JP
Japan
Prior art keywords
information
drug
genotype
patient
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020112023A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022024213A (ja
Inventor
良久 渡邊
良久 渡邊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GENOME PHARMACARE CO., LTD.
Original Assignee
GENOME PHARMACARE CO., LTD.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GENOME PHARMACARE CO., LTD. filed Critical GENOME PHARMACARE CO., LTD.
Priority to JP2020112023A priority Critical patent/JP6893052B1/ja
Priority to PCT/JP2021/019872 priority patent/WO2022004200A1/ja
Priority to JP2022533742A priority patent/JP7671073B2/ja
Application granted granted Critical
Publication of JP6893052B1 publication Critical patent/JP6893052B1/ja
Publication of JP2022024213A publication Critical patent/JP2022024213A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M1/00—Apparatus for enzymology or microbiology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M1/00—Apparatus for enzymology or microbiology
    • C12M1/34—Measuring or testing with condition measuring or sensing means, e.g. colony counters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16Y—INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR THE INTERNET OF THINGS [IoT]
    • G16Y10/00—Economic sectors
    • G16Y10/60—Healthcare; Welfare
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16Y—INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR THE INTERNET OF THINGS [IoT]
    • G16Y20/00—Information sensed or collected by the things
    • G16Y20/40—Information sensed or collected by the things relating to personal data, e.g. biometric data, records or preferences
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16Y—INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR THE INTERNET OF THINGS [IoT]
    • G16Y40/00—IoT characterised by the purpose of the information processing
    • G16Y40/20—Analytics; Diagnosis

Landscapes

  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Computing Systems (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Medical Informatics (AREA)
  • Primary Health Care (AREA)
  • Sustainable Development (AREA)
  • Plant Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Bioethics (AREA)
  • Business, Economics & Management (AREA)
  • Accounting & Taxation (AREA)
  • Development Economics (AREA)
  • Economics (AREA)
  • General Business, Economics & Management (AREA)
  • Public Health (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medical Treatment And Welfare Office Work (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
JP2020112023A 2020-06-29 2020-06-29 投与計画提案システム、方法およびプログラム Active JP6893052B1 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2020112023A JP6893052B1 (ja) 2020-06-29 2020-06-29 投与計画提案システム、方法およびプログラム
PCT/JP2021/019872 WO2022004200A1 (ja) 2020-06-29 2021-05-25 投与計画提案システム、方法およびプログラム
JP2022533742A JP7671073B2 (ja) 2020-06-29 2021-05-25 投与計画提案システム、方法およびプログラム

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2020112023A JP6893052B1 (ja) 2020-06-29 2020-06-29 投与計画提案システム、方法およびプログラム

Publications (2)

Publication Number Publication Date
JP6893052B1 true JP6893052B1 (ja) 2021-06-23
JP2022024213A JP2022024213A (ja) 2022-02-09

Family

ID=76464621

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020112023A Active JP6893052B1 (ja) 2020-06-29 2020-06-29 投与計画提案システム、方法およびプログラム
JP2022533742A Active JP7671073B2 (ja) 2020-06-29 2021-05-25 投与計画提案システム、方法およびプログラム

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022533742A Active JP7671073B2 (ja) 2020-06-29 2021-05-25 投与計画提案システム、方法およびプログラム

Country Status (2)

Country Link
JP (2) JP6893052B1 (https=)
WO (1) WO2022004200A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2023053337A1 (https=) * 2021-09-30 2023-04-06
JP2024538314A (ja) * 2021-11-04 2024-10-18 ウニヴェルズィテート バーゼル 特に臨床制約を条件とした最適な個人投与計画の計算のための方法、システムおよびコンピュータプログラム
JP7855069B2 (ja) 2021-11-04 2026-05-07 ウニヴェルズィテート バーゼル 特に臨床制約を条件とした最適な個人投与計画の計算のための方法、システムおよびコンピュータプログラム

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU750822B2 (en) * 1998-04-03 2002-08-01 Triangle Pharmaceuticals, Inc. Systems, methods and computer program products for guiding the selection of therapeutic treatment regimens
US7461006B2 (en) * 2001-08-29 2008-12-02 Victor Gogolak Method and system for the analysis and association of patient-specific and population-based genomic data with drug safety adverse event data
WO2005038049A2 (en) * 2003-10-06 2005-04-28 Heinrich Guenther System and method for optimizing drug therapy
AU2005321925A1 (en) * 2004-12-30 2006-07-06 Proventys, Inc. Methods, systems, and computer program products for developing and using predictive models for predicting a plurality of medical outcomes, for evaluating intervention strategies, and for simultaneously validating biomarker causality
US20060223058A1 (en) * 2005-04-01 2006-10-05 Perlegen Sciences, Inc. In vitro association studies
JP2009070096A (ja) * 2007-09-12 2009-04-02 Michio Kimura ゲノム情報と臨床情報との統合データベースシステム、および、これが備えるデータベースの製造方法
CN101842496A (zh) * 2007-09-26 2010-09-22 纳维哲尼克斯公司 使用祖先数据进行基因组分析的方法和系统
US8000259B2 (en) * 2009-09-04 2011-08-16 Viasat, Inc. Distributed cache—adaptive multicast architecture for bandwidth reduction
CA2807949C (en) * 2010-08-13 2022-10-25 Intellimedicine, Inc. System and methods for the production of personalized drug products
US20140257851A1 (en) * 2013-03-05 2014-09-11 Clinton Colin Graham Walker Automated interactive health care application for patient care
US20140274764A1 (en) * 2013-03-15 2014-09-18 Pathway Genomics Corporation Method and system to predict response to treatments for mental disorders
US20140274763A1 (en) * 2013-03-15 2014-09-18 Pathway Genomics Corporation Method and system to predict response to pain treatments
JP2020034993A (ja) * 2018-08-27 2020-03-05 秀一 大津 遠隔診療アプリケーションおよびシステム

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2023053337A1 (https=) * 2021-09-30 2023-04-06
JP7769244B2 (ja) 2021-09-30 2025-11-13 Ｎｔｔ株式会社 オンライン調剤システム、情報連携サーバ、オンライン調剤方法、およびプログラム
JP2024538314A (ja) * 2021-11-04 2024-10-18 ウニヴェルズィテート バーゼル 特に臨床制約を条件とした最適な個人投与計画の計算のための方法、システムおよびコンピュータプログラム
JP7855069B2 (ja) 2021-11-04 2026-05-07 ウニヴェルズィテート バーゼル 特に臨床制約を条件とした最適な個人投与計画の計算のための方法、システムおよびコンピュータプログラム

Also Published As

Publication number Publication date
JP2022024213A (ja) 2022-02-09
JPWO2022004200A1 (https=) 2022-01-06
WO2022004200A1 (ja) 2022-01-06
JP7671073B2 (ja) 2025-05-01

Similar Documents

Publication Publication Date Title
Drake et al. A genome-wide association study of bronchodilator response in Latinos implicates rare variants
Siedlinski et al. Genome-wide association study of smoking behaviours in patients with COPD
Breen et al. A genome-wide significant linkage for severe depression on chromosome 3: the depression network study
US8688385B2 (en) Methods for selecting initial doses of psychotropic medications based on a CYP2D6 genotype
Rasmussen‐Torvik et al. High density GWAS for LDL cholesterol in African Americans using electronic medical records reveals a strong protective variant in APOE
Tanner et al. Combinatorial pharmacogenomics and improved patient outcomes in depression: treatment by primary care physicians or psychiatrists
Himes et al. Integration of mouse and human genome-wide association data identifies KCNIP4 as an asthma gene
Rasmussen et al. Genome-wide association study of angioedema induced by angiotensin-converting enzyme inhibitor and angiotensin receptor blocker treatment
Escamilla et al. Genetics of bipolar disorder
Simonson et al. Recent methods for polygenic analysis of genome-wide data implicate an important effect of common variants on cardiovascular disease risk
Liu et al. Biological pathway‐based genome‐wide association analysis identified the vasoactive intestinal peptide (VIP) pathway important for obesity
Moreno et al. Association of GWAS top genes with late-onset Alzheimer’s disease in Colombian population
Douville et al. Polygenic score for the prediction of postoperative nausea and vomiting: A retrospective derivation and validation cohort study
Xu et al. Genome-wide analysis indicates association between heterozygote advantage and healthy aging in humans
Reay et al. Genetic association and causal inference converge on hyperglycaemia as a modifiable factor to improve lung function
Ghouse et al. Polygenic risk score for ACE-inhibitor-associated cough based on the discovery of new genetic loci
Johnston et al. The ACMG SF v3. 0 gene list increases returnable variant detection by 22% when compared with v2. 0 in the ClinSeq cohort
Blue et al. Association of uncommon, noncoding variants in the APOE region with risk of Alzheimer disease in adults of European ancestry
Hotaling et al. Pilot genome-wide association search identifies potential loci for risk of erectile dysfunction in type 1 diabetes using the DCCT/EDIC study cohort
Rajagopal et al. Rare coding variants in CHRNB2 reduce the likelihood of smoking
Zobeck et al. Novel risk factors for glucarpidase use in pediatric acute lymphoblastic leukemia: Hispanic ethnicity, age, and the ABCC4 gene
JP6893052B1 (ja) 投与計画提案システム、方法およびプログラム
Toikumo et al. Multi-ancestry meta-analysis of tobacco use disorder prioritizes novel candidate risk genes and reveals associations with numerous health outcomes
Shirts et al. Evaluation of the gene–age interactions in HDL cholesterol, LDL cholesterol, and triglyceride levels: the impact of the SORT1 polymorphism on LDL cholesterol levels is age dependent
Guillen-Guio et al. Association study of human leukocyte antigen variants and idiopathic pulmonary fibrosis

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200629

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20200629

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20200828

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201020

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210126

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210323

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210402

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210524

R150 Certificate of patent or registration of utility model

Ref document number: 6893052

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250